New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

Biogen · Achievement · November 16, 2026

Biogen shared five-year data from the Clarity AD study long-term extension, showing the long-term effects of lecanemab in patients. The results were presented at the Clinical Trials on Alzheimer’s Disease conference.

Read the announcement

AntSpace’s summary of Biogen’s own announcement: read the original.

More updates from Biogen